Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Devidas M, Dai Y, Reshmi SC, Foster JG, Raetz EA, Borowiltz MJ, Wood B, Carroll WL, McKay PZ, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich J, Minden MD, Zhang Y, Bhatia R, Kohlschmidt J, Mrozek K, Bloomfield CD, Stock W, Kornblau SM , Kantarjian HM, Konopleva MY, Evans WE, Jeha S, C-H P, Yang JJ, Paietta EM, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG
[3] History [edit] Sermorelin acetate was developed as a truncated synthetic analogue of growth hormone-releasing hormone (GHRH) during research into peptide-based regulation of the hypothalamicpituitary axis in the late 20th century
BPC-157 drives angiogenesis and gut protection while TB-500 enhances cellular mobility and reduces inflammation in damaged tissue
They are sometimes discussed together because both have been studied in tissue-repair research models, but the published literature treats them as separate research subjects